TRENDS IN C1 INHIBITOR ANALYSIS REQUESTS BY AGE GROUPS IN PATIENTS SUSPECTED OF HEREDITARY ANGIOEDEMA (HAE) IN COLOMBIA 2015-2025: ESTIMATES WITH MARGINAL EFFECTS MODEL
Author(s)
Pablo Miranda, MD, Msc1, Bautista Hoyos, MD, Esp. Pediatría, Esp. Alergología2, Fernando E. Salcedo Mejía, BEc, MSc3;
1ALZAK Foundation, Cartagena, Colombia, 2Clinica Respiratoria y de Alergias, Cartagena, Colombia, 3Alzak Foundation, Researcher, Cartagena, Colombia
1ALZAK Foundation, Cartagena, Colombia, 2Clinica Respiratoria y de Alergias, Cartagena, Colombia, 3Alzak Foundation, Researcher, Cartagena, Colombia
OBJECTIVES: The average age of onset of symptoms and delay in diagnosis in AEH reported in the medical literature ranges between 10 and 23 years and between 10 and 19 years, respectively. The aim of this study was to estimate the trend of C1 inhibitor analysis requests in patients suspected of HAE over the last decade.
METHODS: Records with a procedures for the evaluation of the C1 esterase inhibitor (C1-INH) (CUPS procedure 906823) selected to identify patients suspected of HAE in the Social Protection Information System (SISPRO) between 2015 and 2025 were included. To determine trends by age group, a poisson marginal effects model was used.
RESULTS: Between 2015 and 2025, 4,272 C1 inhibitor requests were identified. The peak number of requests was in 2014 (1,073). The highest percentage of requests was in the 10 to 14-year age group (8.38%) with an annual rate of 33.5 requests per 100,000. Among those aged 15 to 59, request rates were stable with no significant differences, except in the 20 to 24-year age group, where a significant decrease was observed (20.8 vs 33.5; p <0.05). From of age 60, a marked and progressive decrease in the request rate was observed.
CONCLUSIONS: The trend in C1 inhibitor requests shows a peak in adolescence, stability in adulthood, and a sustained decline in old age.
METHODS: Records with a procedures for the evaluation of the C1 esterase inhibitor (C1-INH) (CUPS procedure 906823) selected to identify patients suspected of HAE in the Social Protection Information System (SISPRO) between 2015 and 2025 were included. To determine trends by age group, a poisson marginal effects model was used.
RESULTS: Between 2015 and 2025, 4,272 C1 inhibitor requests were identified. The peak number of requests was in 2014 (1,073). The highest percentage of requests was in the 10 to 14-year age group (8.38%) with an annual rate of 33.5 requests per 100,000. Among those aged 15 to 59, request rates were stable with no significant differences, except in the 20 to 24-year age group, where a significant decrease was observed (20.8 vs 33.5; p <0.05). From of age 60, a marked and progressive decrease in the request rate was observed.
CONCLUSIONS: The trend in C1 inhibitor requests shows a peak in adolescence, stability in adulthood, and a sustained decline in old age.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EPH33
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Rare & Orphan Diseases